Business Context and Reporting Period
Company: Genworth Financial, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Genworth operates through two primary reportable segments: Enact (private mortgage insurance) and Closed Block (legacy long-term care, life insurance, and annuity products). The company also maintains a "Corporate and Other" segment which includes the start-up CareScout business (aging care services and insurance) and holding company expenses.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $1,777 | $1,786 |
| Net Income (Consolidated) | $79 | $85 |
| Net Income Available to Common Stockholders | $47 | $54 |
| Diluted EPS (Available to Common) | $0.12 | $0.13 |
| Adjusted Operating Income (Excl. Closed Block) | $109 | $114 |
| Net Cash from Operating Activities | $91 | $34 |
| Total Assets | $86,773 | $88,083 |
| Total Liabilities | $76,932 | $78,316 |
| Long-term Borrowings | $1,509 | $1,513 |
| Cash and Cash Equivalents | $2,120 | $2,036 |
Material Changes vs. Prior Period
- Profitability: Net income available to common stockholders decreased by 13% ($7 million) to $47 million, primarily driven by a $53 million swing in net investment gains/losses (from a $27 million gain in 2025 to a $26 million loss in 2026) and higher liability remeasurement losses in the Closed Block segment.
- Investment Performance: Net investment income increased 4% to $766 million, driven by higher yields and income from limited partnerships. However, net investment losses of $26 million were recorded due to portfolio repositioning and lower unrealized gains on limited partnerships compared to the prior year.
- Segment Performance:
- Enact: Adjusted operating income increased 2% to $140 million. New insurance written rose 30% to $12.8 billion. A $39 million reserve release was recorded due to favorable cure performance.
- Closed Block: Adjusted operating loss improved 49% to $32 million (from $63 million loss), driven by less unfavorable mortality in life insurance and favorable mortality in annuities, partially offset by higher claims in long-term care.
- Balance Sheet: Total assets decreased $1.3 billion, largely due to a $667 million decline in fixed maturity securities fair value caused by rising interest rates and widening credit spreads. Total liabilities decreased $1.4 billion, primarily due to higher discount rates reducing the liability for future policy benefits.
Guidance, Outlook, and Risks
- Capital Allocation: The company continues to prioritize returning capital to shareholders. Genworth Financial repurchased $67 million of its own stock in Q1 2026. Enact Holdings returned $99 million in capital to Genworth Holdings in Q1 2026 and announced a new $500 million share repurchase program.
- CareScout Growth: Management expects to invest approximately $50 million to $55 million in CareScout Services in 2026 to scale its aging care network and technology platform.
- Long-Term Care Strategy: The company estimates a cumulative economic benefit of approximately $34.5 billion (net present value) from approved rate increases and benefit reductions in its long-term care in-force rate action plan through Q1 2026.
- Litigation:
- AXA/Santander: Genworth is entitled to share in recoveries from Santander regarding PPI mis-selling. A liability judgment of ~$911 million was awarded to AXA in July 2025, but Santander has appealed. Genworth could receive up to ~$750 million if the appeal is resolved in AXA's favor.
- Class Actions: Several class actions remain pending, including TVPX ARS v. GLAIC (cost of insurance charges) and Trauernicht v. Genworth (ERISA fiduciary duties), though the latter's class certification was reversed by the Fourth Circuit in March 2026.
- Risks: Key risks include the inability to achieve desired levels of in-force rate actions for long-term care, volatility in interest rates impacting investment portfolios and liability valuations, and potential adverse outcomes in pending litigation.
Investor Verification Checklist
- Investment Portfolio Valuation: Verify the impact of rising interest rates and credit spreads on the $45.1 billion fixed maturity securities portfolio, which saw a significant decline in fair value.
- Long-Term Care Assumptions: Review the quarterly liability remeasurement losses ($44 million in Q1 2026) and the progress of in-force rate action approvals to ensure the $34.5 billion cumulative benefit estimate remains achievable.
- Enact Loss Ratios: Monitor the Enact segment's loss ratio (15% in Q1 2026 vs. 12% in Q1 2025) and the sustainability of reserve releases driven by cure performance.
- Litigation Exposure: Track the status of the AXA/Santander appeal and the TVPX ARS class action, as outcomes could materially impact cash flows and reserves.
- CareScout Investment: Assess the burn rate and revenue generation of the CareScout business relative to the planned $50-$55 million investment for 2026.